Deutsch English Français

Contact

EP2877598

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2877598

EP2877598 - MUTATIONS ASSOCIATED WITH RESISTANCE TO INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 04.10.2019 Database last updated on 05.10.2024
Former	Grant of patent is intended Status updated on 03.01.2019
Former	Examination is in progress Status updated on 15.02.2017
Most recent event Tooltip	04.10.2019	Application deemed to be withdrawn	published on 06.11.2019 [2019/45]
Applicant(s)	For all designated states Pharmacyclics LLC 995 East Arques Avenue Sunnyvale, CA 94085 / US
	[2017/20]
Former [2015/23]	For all designated states Pharmacyclics, Inc. 995 East Arques Avenue Sunnyvale, CA 94085 / US
Inventor(s)	01 / CHANG, Betty, Y. 10375 Lindsay Avenue Cupertino, CA 95014 / US
	02 / BUGGY, Joseph, J. 1229 Marilyn Avenue Mountain View, CA 94040 / US
	03 / STEGGERDA, Susanne, M. 1286 8th Avenue San Francisco, CA 94122 / US
	[2015/23]
Representative(s)	Miller, David James, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB
	[N/P]
Former [2015/23]	Irvine, Jonquil Claire HGF Limited 140 London Wall London EC2Y 5DN / GB
Application number, filing date	13745948.3	23.07.2013
	WO2013US51741
Priority number, date	US201261675303P	24.07.2012 Original published format: US 201261675303 P
	US201261682688P	13.08.2012 Original published format: US 201261682688 P
	US201361780652P	13.03.2013 Original published format: US 201361780652 P
	[2015/23]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2014018567
	Date:	30.01.2014
	Language:	EN
	[2014/05]
	Type:	A1 Application with search report
	No.:	EP2877598
	Date:	03.06.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 30.01.2014 takes the place of the publication of the European patent application.
	[2015/23]
Search report(s)	International search report - published on:	EP	30.01.2014
Classification	IPC:	C12Q1/6886	[2018/51]
	CPC:	C12Q1/6886 (EP,KR,US); A61K31/505 (EP,US); A61K31/506 (EP,US); A61K31/519 (EP,US); A61K31/52 (EP,US); A61K45/06 (US); (+) A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP); C07K14/00 (US); C12N9/12 (US); C12N9/16 (US); C12Q1/686 (KR); G01N33/5041 (US); C12Q2600/106 (EP,KR,US); C12Q2600/156 (US); C12Q2600/16 (US); C12Y207/10002 (US); C12Y301/04011 (US); G01N2800/22 (KR) (-)
	Former IPC [2015/23]	C12Q1/68
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/23]
Extension states	BA	22.01.2015
	ME	22.01.2015
Title	German:	MUTATIONEN IM ZUSAMMENHANG MIT DER RESISTENZ GEGENÜBER HEMMERN DER BRUTON-TYROSINKINASE (BTK)	[2015/23]
	English:	MUTATIONS ASSOCIATED WITH RESISTANCE TO INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)	[2015/23]
	French:	MUTATIONS ASSOCIÉES À LA RÉSISTANCE À DES INHIBITEURS DE LA TYROSINE KINASE DE BRUTON (BTK)	[2015/23]
Entry into regional phase	22.01.2015	National basic fee paid
	22.01.2015	Designation fee(s) paid
	22.01.2015	Examination fee paid
Examination procedure	22.01.2015	Examination requested [2015/23]
	22.09.2015	Amendment by applicant (claims and/or description)
	20.11.2015	Despatch of a communication from the examining division (Time limit: M06)
	08.09.2016	Reply to a communication from the examining division
	03.02.2017	Despatch of a communication from the examining division (Time limit: M06)
	11.08.2017	Reply to a communication from the examining division
	22.11.2017	Despatch of a communication from the examining division (Time limit: M06)
	07.09.2018	Reply to a communication from the examining division
	04.01.2019	Communication of intention to grant the patent
	15.05.2019	Application deemed to be withdrawn, date of legal effect [2019/45]
	18.06.2019	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2019/45]
Divisional application(s)	EP19174436.6 / EP3550031
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.11.2015
Request for further processing for:	The application is deemed to be withdrawn due to failure to reply to the examination report
	07.09.2018	Request for further processing filed
	07.09.2018	Full payment received (date of receipt of payment) Request granted
	19.09.2018	Decision despatched
	The application is deemed to be withdrawn due to failure to reply to the examination report
	08.09.2016	Request for further processing filed
	08.09.2016	Full payment received (date of receipt of payment) Request granted
	21.09.2016	Decision despatched
Fees paid	Renewal fee
	10.07.2015	Renewal fee patent year 03
	11.07.2016	Renewal fee patent year 04
	10.07.2017	Renewal fee patent year 05
	10.07.2018	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	31.07.2019	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO2008054827 (PHARMACYCLICS INC [US], et al) [X] 53,67,70,75-77,81,83-85 * paragraph [0118] *;
		[A]WO2008121742 (PHARMACYCLICS INC [US], et al) [A] 1-104 * the whole document *;
		[A]WO2011133609 (TRANSLATIONAL GENOMICS RES INST [US], et al) [A] 1-104 * the whole document *;
		[I] - HANTSCHEL OLIVER ET AL, "Systematic profiling and novel targets of the Bcr-Abl kinase inhibitors imatinib, nilotinib and dasatinib", BLOOD, & 49TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 08 -11, 2007, (200711), vol. 110, no. 11, Part 2, ISSN 0006-4971, page 207B, XP002714015 [I] 1-104 * the whole document *
		[I] - OLIVER HANTSCHEL ET AL, "The Btk Tyrosine Kinase is a Major Target of the Bcr- Abl Inhibitor Dasatinib", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES - PNAS, NATIONAL ACADEMY OF SCIENCES, US, vol. 104, no. 33, doi:10.1073/PNAS.0702654104, ISSN 0027-8424, (20070814), pages 13283 - 13288, (20070807), XP008141134 [I] 1-104 * the whole document * DOI: http://dx.doi.org/10.1073/pnas.0702654104
		[A] - VILLUENDAS R ET AL, "Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach", LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 20, no. 6, doi:10.1038/SJ.LEU.2404197, ISSN 0887-6924, (20060601), pages 1047 - 1054, (20060406), XP008096484 [A] 1-104 DOI: http://dx.doi.org/10.1038/sj.leu.2404197
		[A] - BALASUBRAMANIAN SRIRAM ET AL, "Identification of MicroRNA Markers of Sensitivity to the Novel Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 in Non-Hodgkin's Lymphoma", BLOOD, & 50TH ANNUAL MEETING OF THE AMERICAN- SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2008, (200811), vol. 112, no. 11, ISSN 0006-4971, pages 1155 - 1156, XP002714016 [A] 1-104 * the whole document *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p